Clear cell renal cell carcinoma (ccRCC) is one of the most common malignant tumors in the urinary system. Surgical intervention is the preferred treatment for ccRCC, but targeted biological therapy is required for postoperative recurrent or metastatic ccRCC. Autophagy is an intracellular degradation system for misfolded/aggregated proteins and dysfunctional organelles. Defective autophagy is associated with many diseases. Mul1 is a mitochondrion-associated E3 ubiquitin ligase and involved in the regulation of divergent pathophysiological processes such as mitochondrial dynamics, and thus affects the development of various diseases including cancers. Whether
| INTRODUC TI ON
Clear cell renal cell carcinoma (ccRCC) is one of the most common urinary tract malignant tumors with high morbidity and mortality. In the past two decades, the incidence of ccRCC worldwide has doubled, and the death toll is rising at a rate of 1% per year. 1 Development of ccRCC is difficult to predict, although epidemiological studies have found that tobacco consumption, obesity, hypertension and chronic nephropathy can induce ccRCC. [1] [2] [3] [4] [5] Localized ccRCC can be treated with partial, radical nephrectomy or thermal ablation. [6] [7] [8] However, approximately 30% of patients with localized ccRCC who underwent surgical intervention developed further metastatic ccRCC (mccRCC) and required systemic treatment. 7 Although many targeted drugs and biologicals for ccRCC are currently in the research and development stage, their efficacy remains to be explored. Hence, the identification of new and effective biomarkers is essential for a better understanding of the biological progression of ccRCC and to improve the diagnosis and prognosis of this cancer in clinical practice.
Autophagy is an intracellular degradation system that captures damaged or non-functional proteins and organelles and transports them to lysosomes for degradation. 9 It plays an important homeostatic role in controlling the quality and quantity of proteins and organelles. Autophagy processes include cargo sequestration, transport to lysosomes, cargo degradation and recycling of degraded products, and the function of each different stage may be regulated differentially. 10 LC3 functions as a core protein in autophagy and is mainly used for the recognition and recruitment of autophagy cargo.
It elongates and seals the cargo and transports it to the autophagosomes. 11 At present, there are conflicting reports about the roles of autophagy in the development of cancer. Some studies related to breast cancer, colon cancer, lung cancer, prostate cancer and pancreatic cancer have shown that autophagy mainly promotes cancer development, [12] [13] [14] [15] [16] whereas others related to liver cancer and ccRCC have shown the opposite results in that autophagy suppresses cancer development. [17] [18] [19] Our previous study found that microtubule-associated protein family 1 (MAP1S) can promote autophagy clearance of lipid droplets and reduce DNA double-strand breaks and genome instability, consequently suppressing the development of ccRCC and promoting patient survival. 19 Similarly, other groups have shown that autophagy can suppress ccRCC development. [20] [21] [22] Therefore, whether autophagy promotes or inhibits cancer development or whether autophagy has different regulatory mechanisms for cancer development in different tissues requires further investigation. 9, 23 Mitochondrial E3 ubiquitin ligase 1 (Mul1), a multifunctional mitochondrial membrane-associated protein located on the outer membrane of the mitochondrion with two transmembrane domains and one Ring-finger domain, 24 regulates different biological processes such as mitochondrial dynamics, cell growth, apoptosis and mitophagy (autophagy degradation of mitochondria), through ubiquitination and SUMOylation. [25] [26] [27] Mitophagy and mitochondrial dynamics cause frequent changes in both quantity and morphology of cells and organelles. 28 The imbalance of homeostasis is clearly associated with diseases such as Parkinson's disease, viral infection and carcinomas. [29] [30] [31] [32] [33] It was reported that Mul1 mediates the ubiquitination of Akt and HSPA5 to inhibit the development of head and neck cancer. 32, 33 Herein, we show that Mul1 promotes autophagy flux and suppresses ccRCC development with cell culture models and its loss of expression in ccRCC tissues from patients may lead to the blockade of autophagy flux, development of ccRCC and impairment of survival. 
| MATERIAL S AND ME THODS

| Patients and tissue samples
| Generation of stable cell lines
| Assays of cell growth rates and migration
Cell growth rates were carried out through the CCK-8 proliferation assay. The same number of cells were seeded and cultured in normal medium. After being cultured for 4 hours, 24 hours, 48 hours and 72 hours, cells were treated with 20 μL CCK-8 solution for 2 hours and subjected to absorbance measurement at 450 nm by microplate reader. Cell migration rates were analyzed by wound-healing assay.
Cells grown to full confluence on culture plates were treated with 4 μg/mL mitomycin (Cat#: 10107409001) from Roche for 2 hours and scratched. Cells were continuously cultured and observed under a microscope to measure distances of cell migration at specific time points.
| Assays of the impact of Mul1 on autophagy
Stable cell lines with suppression or elevation of Mul1 were cultured to full confluence and treated with 10 μmol/L Bafilomycin A1 (S1413) from Selleck for 6 hours. Cells were collected and lysed to prepare cell lysates. Cell lysates with the same amount of total protein as measured by the bicinchoninic acid (BCA) method were separated on SDS-PAGE and separated proteins were transferred to membranes to conduct immunoblot with Mul1 antibody as described above. LC3 antibody (ab192890) was from Abcam, and P62 antibody (#88588) was from CST. Levels of adipose differentiation-related protein (ADFP) in renal tissues from ccRCC patients from our hospital were analyzed by immunohistochemical staining with ADFP-specific antibody (cat# ab181452) from Abcam.
| Assigment of immunoreactivity scores and statistical analyses
To quantify the levels of Mul1 protein in renal tissues from ccRCC patients as shown by immunohistochemical staining, five random fields captured under microscope with a magnitude of 400-fold were selected. Percentage of positively stained cells to total cells was calculated and scored with the standard: <5% (0 points), 6%-25% (1 point), 26%-50% (2 points), 51%-75% (3 points), and >75% (4 points).
Staining intensity was visually scored and stratified according to the following criteria: no staining (0 points), mild (1 point), moderate (2 points), and strong (3 points). The final immunoreactivity score of each case was calculated by adding the two scores based on the immunostaining percentage and the immunostaining intensity. 
| RE SULTS
| Expression of Mul1 protein is reduced in human ccRCC tissues
To probe the role of Mul1 protein in the development of ccRCC, we conducted preliminary screening of the levels of Mul1 protein in ccRCC tissues and their respective adjacent normal renal tissues from 11 patients collected in our hospital by immunohistochemical staining. It was found that the levels of Mul1 protein were high in the distal convoluted tubules and the proximal convoluted tubules of normal renal tissues but near negative in ccRCC tissue from the same patients ( Figure 1A-D) .
The lower levels of Mul1 expression in ccRCC tissues compared to their respective normal renal tissues were further confirmed with tissues from three patients by immunoblot analysis (Figure 1E Table 1 ). Therefore, the expression of Mul1 protein is dramatically reduced in ccRCC tissues.
| Reduced expression of Mul1 predicts poor prognosis of human patients with ccRCC
We examined the levels of Mul1 mRNA and protein in cultured cells including HK-2 (human kidney 2), an immortalized proximal (Table 2 ). In agreement with results related to protein levels, patients diagnosed with higher clinical stage and higher degree of tumor invasion expressed lower levels of Mul1 mRNA and protein (Tables 1 and 2). Further analyses indicated that patients with lower levels of Mul1 mRNA had significantly poorer overall and disease-free survival than those with higher levels of Mul1 mRNA ( Figure 2D,E) . In addition, univariate analysis and further multivariate analysis indicated that lower levels of Mul1 mRNA but higher degree of tumor invasion and pathological grade showed higher hazard ratio to disease-free survival (Table 3) . Therefore, reduced levels of Mul1 predict more malignant ccRCC and poor prognosis of ccRCC patients.
| Mitochondrial E3 ubiquitin ligase 1 inhibits the growth and migration of ccRCC cells
In order to test the roles of Mul1 in tumorigenesis, we generated stable cell lines with reduced or overexpressed levels of Mul1 in the background of cancer cell 769-P. Treating 769-P cells with two types of Mul1-specific siRNA molecule led to successful suppression of Mul1 protein ( Figure 3A,B) , whereas adding a plasmid carrying the Mul1 gene did not increase the levels of Mul1 protein ( Figure 3C,D) . Further measurements with RT-PCR indicated that the treatment with siRNA led to a significant reduction whereas treatment with plasmid led to a significant increase in the levels of Mul1 mRNA (Figure 3E,F) .
To test the impact of Mul1 on growth and migration, we conducted CCK-8 proliferation assay and wound-healing experiments using stable cell lines. Suppressing the expression of Mul1 led to a significant increase in cell growth rates ( Figure 4A ). Because of the inefficiency to increase the levels of Mul1 protein by overexpression, cells transfected with Mul1 expression plasmid did not show any significant impact on growth as expected ( Figure 4B) . Similarly, suppressing expression of Mul1 promoted cell migration ( Figure 4C,D) , but the overexpression of Mul1 did not change the migration rates as expected ( Figure 4C,E) . In general, Mul1 inhibits the growth and migration of ccRCC cells.
| Mitochondrial E3 ubiquitin ligase 1 promotes autophagy flux in ccRCC
Although it was observed that cells transfected with Mul1-expressing plasmid showed higher levels of Mul1 mRNA ( Figure 3F 
| D ISCUSS I ON
As a common urological malignancy, based on epidemiological data, ccRCC was shown to be caused by obesity, smoking, hypertension, chronic kidney disease and type 2 diabetes, suggesting the potential to prevent the development of ccRCC. [2] [3] [4] [5] Established surgical treatments have shown good results for the treatment of localized ccRCC. [6] [7] [8] However, the treatment for postoperative recurrence or concurrent metastasis of mccRCC still lacks any specific therapeutic drug that can improve the survival of ccRCC patients.
Currently, the relationship between autophagy and cancer is still unclear. In general, basal autophagy flux inhibits early tumor development by maintaining homeostasis and suppressing genomic damage events. 33 Because the metabolic and biosynthesis requirements of tumor cells are significantly increased, it seems that cancer cells depend more on autophagy than do normal cells. Therefore, some suggest that autophagy promotes the development of advanced tumors. 34 However, the latest research findings show that the development of cancer is often accompanied by the decline or loss of autophagy. When autophagy flux is blocked, cancer cells accumulate more genomic errors and become more malignant. 35 Our previous results showed that promoting autophagy is beneficial to inhibit the development of hepatocellular carcinoma and ccRCC and to improve patient survival. 35 It was found that autophagy flux was relatively reduced in ccRCC and negatively correlated with tumor clinical stage and pathological grade. 17 Mitochondrial E3 ubiquitin ligase 1 was originally discovered as an E3 ligase of ubiquitination. It promotes autophagy degradation of mitochondria by interacting with a specific E2 ubiquitination-binding enzyme and autophagy-related protein GABARAP, 25 or mediating the ubiquitination of autophagy upstream protein ULK1. 27 
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